围产期心境与焦虑障碍诊断生物标志物:现状与新兴前沿
本文为叙述性综述,系统梳理2000至2020年传统循环因子生物标志物(维生素与矿物质、炎症标志物、类固醇/激素)及2020年后新兴标志物(核酸、细胞外囊泡、蛋白质组学、功能性免疫细胞谱)在围产期心境与焦虑障碍(PMADs)诊断中的研究现状。目前尚无任何候选生物标志物进入临床实施,主要挑战包括样本复杂性、标志物丰度低、人群变异及可重复性与验证问题。未来需标准化样本流程、开展纵向研究、整合血液与脑影像等多模态指标并深化表型分析。
要点
- PMADs诊断仍缺乏临床可用的生物标志物,现有候选均未实现转化。
- 传统标志物包括维生素与矿物质、炎症标志物及类固醇/激素,新兴标志物包括核酸、细胞外囊泡、蛋白质组学与功能性免疫细胞谱。
- 单标志物依赖过度简化复杂疾病,需标准化流程、纵向设计与多模态整合提升精准度。
核心结论
- PMADs领域虽已报道多种循环因子候选生物标志物,但尚无任何标志物被临床实施用于诊断或预测。
- 生物标志物缺乏一致性,依赖单一标志物会过度简化复杂疾病,需多模态与纵向研究推进转化。
研究设计与样本
- 叙述性综述,检索并批判性评估PMADs循环因子生物标志物文献。
- 传统标志物纳入2000至2020年发表的研究,新兴标志物纳入2020年以来发表的研究。
主要发现
- 传统候选标志物涵盖维生素与矿物质、炎症标志物、类固醇/激素三大类。
- 新兴候选标志物涵盖核酸、细胞外囊泡、蛋白质组学与功能性免疫细胞谱。
- 现有文献报道许多潜在候选标志物,但均未在临床中实施。
临床怎么用
- 临床暂不能将现有循环因子生物标志物用于PMADs的诊断或预测。
- 未来转化需优先标准化样本采集流程并选择匹配良好的研究组。
- 需开展纵向研究并将血液标志物与脑影像及其他生物学指标整合。
局限性
- 生物样本复杂、标志物丰度低,增加检测与验证难度。
- 患者人群间存在变异,影响标志物一致性。
- 大型多样样本中的可重复性与验证存在问题。
- 依赖单一标志物会过度简化复杂疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Perinatal mood and anxiety disorders (PMADs) are a spectrum of mental health conditions that are the most common pregnancy-related complications in the United States. Despite great strides in developing appropriate pharmacological and psychological treatments, there continues to be a lack of biological measures for diagnosis and prediction of PMADs. Such measures could be effectively utilized to subtype and mechanistically explore PMADs and appropriately leverage mental health care resources. While the literature evidences many potential candidates, none have been clinically implemented. To move the field forward, this narrative review curates and critically evaluates the current state of the literature on circulating factor biomarkers for PMADs. Here, we review 2 categories of PMAD biomarkers: conventional, well-studied factors published between 2000 and 2020 and recently emergent factors published since 2020. The categories of conventional factors reviewed include vitamins and minerals, inflammatory markers, and steroids/hormones. Recently emergent categories of factors include nucleic acids, extracellular vesicles, proteomics, and functional immune cell profiles. The promise of emergent technologies is highlighted. Challenges are discussed and include biological sample complexity, low biomarker abundance, variability across patient populations, and issues with reproducibility and validation in large and diverse samples. Biomarkers often lack consistency, and reliance on single markers oversimplifies complex diseases. Priorities for future work include standardizing sample protocols, selecting well-matched study groups, conducting longitudinal studies, integrating blood biomarkers with brain and other biological measures, and deep phenotyping to improve diagnostic and predictive precision and personalized care. As biomarkers are revealed and validated, advances can be made toward improving maternal health during the perinatal period and beyond.
引用
- Kiel M, Pawlak S, van Dijk S, et al. Biomarkers for the Diagnosis of Perinatal Mood and Anxiety Disorders: Existing Landscapes and Emerging Frontiers. Biol Psychiatry. 2025. PMID: 40912620. doi:10.1016/j.biopsych.2025.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。